Singh, Anmol
Locke, Susan C.
Wolf, Steven P.
Albrecht, Tara A.
Troy, Jesse D.
Derry, Heather
El-Jawahri, Areej
LeBlanc, Thomas W. http://orcid.org/0000-0002-0546-7895
Article History
Received: 29 March 2021
Accepted: 9 August 2021
First Online: 17 August 2021
Declarations
:
: The Institutional Review Board of the Duke University School of Medicine approved this protocol. Informed consent was obtained from all individual participants included in the study.
: Participants provided signed informed consent to participate in the parent study that led to the dataset analyzed for this report. No consent could be provided for this secondary analysis, which was approved and within the scope of the IRB’s approval of this study and the analysis of resulting data.
: Participants provided signed informed consent to participate in the parent trial, which includes acknowledgment that resulting insights may be published. No separate consent could or should be contained for this secondary analysis of previously conducted data, nor is this required by the IRB.
: T.W.L. reports the following disclosures from the past 24 months: personal fees for consulting or advisory boards from AbbVie, Agios, AstraZeneca, Amgen, Astellas, CareVive, BMS/Celgene, Daiichi-Sankyo, Flatiron, Heron, Pfizer, and Seattle Genetics; royalties from UpToDate; speakers bureau fees from Agios, AbbVie, and BMS/Celgene; grants and/or research contracts from the American Cancer Society, AstraZeneca, BMS, Jazz Pharmaceuticals, the NINR/NIH, and Seattle Genetics.